Pharmacoeconomics is essential to reduce burden for patients in the terms of cost and improve the therapeutic effectiveness by selecting alternative treatments. Physician and pharmacist plays an important role in selecting drugs and treatment alternatives. So, proper selection helps to minimize the cost of therapy in patients. Research studies on pharmacoeconomics helps to know the burden of patients paying for their illness.
Quality Use of Medicines means:
• Selecting management options wisely by:
Considering the place of medicines in treating illness and maintaining health, and
recognising that there may be better ways than medicine to manage many disorders.
• Choosing suitable medicines if a medicine is considered necessary so that the best available option is selected by taking into account:
- the individual
- the clinical condition
- risks and benefits
- dosage and length of treatment
- any co-existing conditions
- other therapies
- monitoring considerations
- costs for the individual, the community and the health system as a whole.
Quality Use of Medicines means:
• Selecting management options wisely by:
Considering the place of medicines in treating illness and maintaining health, and
recognising that there may be better ways than medicine to manage many disorders.
• Choosing suitable medicines if a medicine is considered necessary so that the best available option is selected by taking into account:
- the individual
- the clinical condition
- risks and benefits
- dosage and length of treatment
- any co-existing conditions
- other therapies
- monitoring considerations
- costs for the individual, the community and the health system as a whole.
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Slides includes ADR monitoring process, Safety reporting, what is pharmacovigilance, types of ADR, basic terms in ADR monitoring, what is PvPI in India, role. stakeholders, ADR reporting form, Apps, Role of community Pharmacist in ADR monitoring, Importance of ADR monitoring, etc.
In this presentation i have tried to explain in detail about the measurements of the outcomes which are used in epidemiology such as prevalence, incidence, fatality rate, crude death rate etc.
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenpavithra vinayak
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Slides includes ADR monitoring process, Safety reporting, what is pharmacovigilance, types of ADR, basic terms in ADR monitoring, what is PvPI in India, role. stakeholders, ADR reporting form, Apps, Role of community Pharmacist in ADR monitoring, Importance of ADR monitoring, etc.
In this presentation i have tried to explain in detail about the measurements of the outcomes which are used in epidemiology such as prevalence, incidence, fatality rate, crude death rate etc.
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenpavithra vinayak
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
Outcomes, health economics and pharmacoeconomicsDureshahwar khan
Pharmacoeconomics can be regarded as a branch of health economics which deals with identifying, measuring, and comparing the costs and consequences of pharmaceutical products and services. Some of the concepts involved in pharmacoeconomic analysis include cost minimization, cost effectiveness, cost benefit, and cost utility analysis.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
1. PHARMACOECONOMICS: TO REDUCE
BURDEN FOR PATIENTS
BY: Dr. VISHWAS A T L, Pharm.D
ASSISTANT PROFESSOR
DEPARTMENT OF PHARMACY PRACTICE
BHARATHI COLLEGE OF PHARMACY
BHARATHINAGARA - 571422
3. HISTORY
Pharmacy was finally recognized as a clinical discipline within the healthcare
system in the early 1960s.
Pharmacoeconomics developed its roots in 1970s.
The first book on health economics was published in 1973
In 1978, Mc Ghan, Rowland, and Bootman from the University of Minnesota
introduced the concept of cost-benefit and cost effectiveness analysis.
Bootman by utilizing sophisticated pharmacokinetic protocols, published an
cost-benefit analysis research article on aminoglycoside dosages in 1979.
In 1983, Ohio State University College of Pharmacy initiated a specialized
pharmacy academic program with the objective of providing an overview of the
application of cost benefit and cost effective analysis in healthcare, with emphasis
on their application to the delivery of pharmaceutical care.
4. Continue……
Initially, defined as “Analysis of the costs of drug therapy to healthcare systems
and society”.
The actual term “Pharmacoeconomics” first appeared in the literature in 1986
when Townsend’s work was published to highlight the need to develop research
activities in this new discipline.
In 1992, a journal named “Pharmacoeconomics” was launched.
5. DEFINITIONS
Economics: It is the study of allocation of limited or scarce resources or inputs
among alternatives to satisfy wants of outputs.
Health economics: It evaluates the behaviour of individuals, firms and markets in
health care.
Outcomes research: It is a research which assesses the effects of programs,
policies, and medical interventions on the health status of the patient, focuses on
clinical, humanistic and economic outcomes.
Pharmacoeconomics: It comes under the economic outcomes which identifies,
measures, and compares the costs and consequences of the use of pharmaceutical
products and services.
7. GOALS
The goal of a pharmacoeconomic study is to determine whether the expense
incurred by the use of a new medication is justified in comparison with the
cost of existing medication.
Also includes potential cost savings resulting from a decrease in the number
of physician visits, emergency room visits, length and number of
hospitalizations, ancillary transportation costs, and the number of days of
work lost by patients taking the new medication.
8. NEEDS OF PHARMACOECONOMICS
To decrease the burden for patients, healthcare professionals and public.
It is essential to find the optimal therapy at the lowest price.
In government sector helps to determine program benefits and its operating expense.
In pharmaceutical manufacturing industries helps to decide among specific research
and development alternatives.
In private sector it can be used for designing insurance benefit coverage.
Additionally, it describes the economic relationship involving drug research, drug
production, distribution, storage, pricing and its use by the society.
9. Costs
Cost is defined as the value of the resources consumed a drug therapy of interest. It
is the amount paid to the suppliers by the patient.
Direct medical cost
Costs
Direct non-medical cost
Indirect cost
Intangible costs
10. TYPES OF COSTS
Health care costs are categorised as..
Direct medical cost: This is what is paid for specialized health resources and
services. It includes the physician’s salaries, the acquisition cost of medicine,
consumables associated with drug administration, staff time in preparation and
administration of medicines, laboratory costs of monitoring for effectiveness and
adverse drug reactions.
Direct non-medical cost : This includes cost necessary to enable an individual
receive medical care such as lodging, special diet and transportation, lost work
time (important to employers) such as acute Otitis media in paediatric patients
with professional parents who lost work time during the treatment of their kid.
11. Indirect cost : This is the cost incurred by the patient, family, friends or society.
Many of these are difficult to measure, but should be of concern to society as a
whole. This includes productivity loss in the society, unpaid care givers, lost wages,
expenses of illness borne by patients, relatives, friends, employers and the
government and loss of leisure time.
Intangible costs: These are costs related with the patient’s pain and suffering,
worry and other distress of the family members of a patient, effect on quality of life
and health perceptions. For example, patients of rheumatoid arthritis, cancer or
having terminal illnesses in which quality of life is suffered due to adverse reactions
of the drug treatment.
Total costs = Direct cost+ Indirect costs + Intangible costs
12. OUTCOME/ CONSEQUENCES
Consequence is defined as the effects, outputs, or outcomes of the program of drug
therapy of interest.
There are mainly three types of outcomes which includes,
1. Economic outcomes
Reduction in resource use or saving.
Savings due to treatment.
Production gain to return to work.
2. Clinical outcomes: Medical event that occur as a result of disease or treatment.
Laboratory values
Number of lives saved
Number of deaths prevented
Number of disability days reduced
13. 3. Humanistic outcomes: Effect on patient’s functional status or quality of life.
Changes in health related quality of life measures ( HRQOL)
Quality adjusted life years ( QALY)
Outcome can also be,
- Positive: desired effect of drug.
- Negative : undesired or adverse effect of drug
- Pharmacoeconomic evaluation include both.
14. PHARMACOECONOMIC EVALUATIONS
Pharmacoeconomic evaluations include any study designed to assess the costs
(resources consumed) and consequences (clinical, humanistic) of alternative
therapies. There are five major types of Pharmacoeconomics analyses. In each type
of analysis, economic inputs are measured in dollars and the measurement of
outcomes differs.
Cost-minimization analysis
Cost-effectiveness analysis
Cost-utility analysis
Cost-benefit analysis
Cost of illness
15. COST-MINIMIZATION ANALYSIS
Cost-minimization analysis (CMA) involves the determination of the least costly
alternative when comparing two or more treatment alternatives.
With CMA, the alternatives must have an assumed or demonstrated equivalency in
safety and efficacy (i.e., the two alternatives must be equivalent therapeutically).
Once this equivalency in outcome is confirmed, the costs can be identified,
measured, and compared in monetary units (dollars).
CMA is a relatively straightforward and simple method for comparing competing
programs or treatment alternatives as long as the therapeutic equivalence of the
alternatives being compared has been established.
If no evidence exists to support this, then a more comprehensive method such as
cost-effectiveness analysis should be employed.
16. Objective: The objective of this method is to select the least costly among multiple
equivalent interventions.
Advantages:
CMA is a relatively straightforward and simple method for comparing competing
programs or treatment alternatives.
Employing CMA is appropriate when comparing two or more therapeutically
equivalent agents or alternate dosing regimens of the same agent.
Disadvantages:
It cannot be used to evaluate programmes or therapies that lead to different
outcomes.
Example: - If a hospital decides to introduce compulsory prescribing of generic
names of drugs instead of their brand names, then the pharmacoeconomic evaluation
of this would be done by CMA.
17. COST-EFFECTIVENESS ANALYSIS (CEA)
CEA is a technique designed to assist a decision-maker in identifying a preferred
choice among possible alternatives.
Generally, cost-effectiveness is defined as a series of analytical and mathematical
procedure that aid in the selection of a course of action from various alternative
approaches.
The costs of drug treatments include acquisition costs, physician involvement, and
nursing costs for administration of the drug.
The effectiveness of drug treatment is measured in tangible measures such as
length of hospital stay, duration of treatment required, and mortality rate.
The key measure of the evaluations is the incremental cost effectiveness ratio
(ICER), which can be determined as follows:
Incremental cost effectiveness ratio= Cost of drug A - Cost of drug B
Benefits of drug A - Benefits of drug B
18. Advantages:
CEA evaluates multiple drug treatments for the same condition.
The results of a CEA are expressed as cost/outcome for both therapies.
Disadvantages:
It does not allow comparisons to be made between two totally different areas of medicine with
different outcomes.
Example:
In a treatment of illness the cost of drug A is 300 rs and cure rate will be 67.4, where as cost of drug
B is 200 rs and cure rate will be 45.6. calculate average cost effectiveness.
Drug A = 400 Rs= 5.9 Rs/ successful treatment, Drug B = 200 Rs = 4.3 Rs/ Successful treatment
67.4 45.6
ICER = 400-200 = 200 = 9.17 rupees/ Additional successful rate
67.4 – 45.6 21.8
Interpretation: It costs an additional 9.17 rupees to gain one additional successful case with drug A
20. COST-UTILITY ANALYSIS
Cost-utility analysis (CUA) is an economic tool in which the intervention
consequences is measured in the terms of quantity and quality of life.
Results often are expressed as cost per quality-adjusted life-year (QALY) gained.
Outcomes are adjusted for quality by using "utility" values or weights.
Results of CUA are also expressed in a ratio, a cost-utility ratio (C:U ratio).
QALYs represent the number of full years at full health that are valued
equivalently to the number of years as experienced.
In this context, utility represents the preference expressed for a particular health
state.
Utility values range from 0 to 1, with 0 being death and 1 representing perfect
health.
21. Advantages
CUA is the most appropriate method to use when comparing programs and
treatment alternatives that are life extending with serious side effects.
CUA is a method for comparing treatment alternatives that integrates patient
preferences and health related quality of life.
CUA can compare cost, quality, and the quantity of patient-years.
Disadvantages
CUA is employed less frequently than other economic evaluation methods
because of a lack of agreement on measuring utilities, difficulty comparing
QALYs (quality adjusted life years) across patients and populations.
Pharmacoeconomists sometimes want to include a measure of patient preference
or quality of life when comparing competing treatment alternatives.
22. Example: Comparing patients with and without treatment for illness as follows,
Patient with treatment Patient without treatment
Estimated survival = 10 years Estimated survival = 5 years
Estimated quality of life = 0.7 Estimated quality of life = 0.5
(Relative to ‘perfect health’) (‘Relative to perfect health’)
QUALYs = 10 X 0.7= 7.0 QUALYs = 5X0.5= 2.5
QUALY gain from treatment ‘X’ = 7-2.5 =4.5 QUALYs
If the cost of treatment is 6000 rupees then the cost per QUALY is 1,333 per
QUALY.
( It is obtained by 6,000 rupees/4.5 additional QUALYs )
23. COST-BENEFIT ANALYSIS
CBA is the most comprehensive and the most difficult of all economic evaluation
techniques.
Cost-benefit analysis (CBA) is a method that allows for the identification,
measurement, and comparison of the benefits and costs of a program or treatment
alternative.
Both the costs and the benefits are measured and converted into equivalent dollars
in the year in which they will occur.
Thus, totally different interventions can be compared, making it a useful tool for
resource allocation by policy-makers.
CBA also can be used when comparing programs with different objectives
because all benefits are converted into dollars and to evaluate a single program or
compare multiple programs.
24. Advantages
It is a basic tool that allows for the identification, measurement, and comparison
of the benefits and costs of a program or treatment alternative.
CBA should be employed when comparing treatment alternatives in which the
costs and benefits do not occur simultaneously.
Both the costs and the benefits are measured and converted into equivalent dollars
in the year in which they will occur.
Disadvantages
One limitation of cost-benefit analysis lies in the difficulty of placing a dollar
value on health.
The most difficult and challenging part of CBA lies in calculating the benefits in
economic terms.
25. COST OF ILLNESS
A cost-of-illness (COI) evaluation identifies and estimates the overall cost of a
particular disease for a defined population.
This evaluation method is often referred to as burden of illness and involves
measuring the direct and indirect costs attributable to a specific disease.
The costs of various diseases, including diabetes, mental disorders, and cancer, in
the United States have been estimated.
By successfully identifying the direct and indirect costs of an illness, one can
determine the relative value of a treatment or prevention strategy.
COI evaluation is not used to compare competing treatment alternatives but to
provide an estimation of the financial burden of a disease. Thus, the value of
prevention and treatment strategies can be measured against this illness cost.
26. STEPS IN PHARMACOECONOMIC ANALYSIS
A well-designed pharmacoeconomic analysis involves 10 steps:
Defining the problem
Determining the study's perspective,
Determining the alternatives and outcomes,
Selecting the appropriate pharmacoeconomic method,
Placing monetary values on the outcomes,
Identifying study resources,
Establishing the probabilities of the outcomes,
Applying decision analysis,
Discounting costs or performing a sensitivity or incremental cost analysis, and
Presenting the results, along with any limitations of the study.
27. PERSPECTIVES OF PHARMACO-ECONOMICS
1. Patient Perspective:- Patient perspective is paramount because patients are the
ultimate consumers of healthcare services. Costs from the viewpoint of patients are
basically what patients pay for an item or administration that is, the segment not
secured by protection.
2. Payer Perspective:- Payers include insurance companies, employers, or the
government. From this perspective, costs represent the charges for healthcare
products and services allowed or reimbursed by the payer. The primary cost for a
payer is of a direct nature. However, indirect costs, such as lost workdays
(absenteeism), being at work but not feeling well and therefore having lower
productivity (presenteeism), also can contribute to the total cost of healthcare to
the payer.
28. CONTINUE…..
3. Societal Perspective:- Theoretically, all direct and indirect costs are included in
an economic evaluation performed from a societal perspective. Costs from this
perspective include patient morbidity and mortality and the overall costs of
giving and receiving medical care. An evaluation from this perspective also
would include all the important consequences an individual could experience.
4. Provider Perspective:- Costs from the provider's perspective are the actual
expense of providing a product or service, regardless of what the provider
charges. Providers can be hospitals or private practice physicians. From this
perspective, direct costs such as drugs, hospitalization, laboratory tests, supplies,
and salaries of healthcare professionals can be identified, measured, and
compared.
29. PHARMACOECONOMICS APPLICATIONS IN PHARMACY
The application of pharmacoeconomics also can be useful for making a decision
about an individual patient's therapy.
Pharmacoeconomic principles and methods have been applied commonly to assist
clinicians and practitioners in making more informed and complete decisions
regarding drug therapy.
Electing the most cost-effective drugs for an organizational formulary is important.
However, it is equally important to determine the most appropriate way to use and
prescribe these agents.
The most recent application of pharmacoeconomic principles and methods has been
for justifying the value of various healthcare services, particularly pharmacy services.
Pharmacoeconomic data can be a powerful tool to support various clinical decisions,
ranging from the level of the patient to the level of an entire healthcare system.
30. One of the primary applications of pharmacoeconomics in clinical practice today is to
aid clinical and policy decision making. Through the appropriate application of
pharmacoeconomics, practitioners and administrators can make better, more informed
decisions regarding the products and services they provide.
Healthcare practitioners, regardless of practice setting, can benefit from applying the
principles and methods of pharmacoeconomics to their daily practice settings. Applied
pharmacoeconomics is defined as putting pharmacoeconomic principles, methods, and
theories into practice to quantify the value of pharmacy products and pharmaceutical
care services used in real-world environments.
Cost-benefit analysis is a method that allows for the identification, measurement, and
comparison of the benefits and costs of a program or treatment alternative. The benefits
realized from a program or treatment alternative are compared with the costs of
providing it.
Cost-minimization analysis involves the determination of the least costly alternative
when comparing two or more treatment alternatives